Brief: Prelude Therapeutics Announces Third Quarter 2020 Financial Results
10/11/2020 13:06
Nov 10 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* PRELUDE THERAPEUTICS ANNOUNCES THIRD QUARTER 2020
FINANCIAL
RESULTS
* Q3 LOSS PER SHARE $5.25
* Q3 EARNINGS PER SHARE ESTIMATE $-0.43 -- REFINITIV IBES
DATA
Source text for Eikon: ID:nGNXbbxrKK
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview